Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China revises GMPs

This article was originally published in The Tan Sheet

Executive Summary

China's State Food and Drug Administration proposes revised good manufacturing practices that would give nonprescription drug firms three years to implement changes once guidelines are issued. Guo Jingwu, director of drug safety in SFDA's Inspection Department, said June 2 at a conference in Shanghai that SFDA adopted the guidelines May 28 and expects to issue the document in June. China's Ministry Of Health is reviewing the guidance and will submit it to the World Trade Organization before releasing it. SFDA will give companies three years to implement changes, though firms that manufacture injection drugs and products on China's Essential Drug List will have two years. The GMP revision, a key goal for SFDA in 2010, is part of the agency's work to align China's pharmaceutical and medical device regulations with international standards (1"The Tan Sheet" March 8, 2010)

You may also be interested in...

China State FDA Includes Drug GMPs In Expected 2010 Reforms

China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question manufacturers have is, how soon

QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts